IP Group sold a $5m stake to incoming shareholder Celltrion as part of a series A round for Iksuda, a spinout of Bath originally called Glythera.
Iksuda Therapeutics, a UK-based antibody drug conjugates developer spun out of University of Bath, has closed a $47m series A round that included a $5m stake sale by commercialisation firm IP Group to an incoming shareholder, biopharmaceutical firm Celltrion.
Celltrion co-led the round with Premier Partners, Mirae Asset and the latter’s subsidiaries.
IP Group owns a 19.4% undiluted stake in Iksuda following the deal.
Founded in 2007 as Glythera, Iksuda is working on antibody drug conjugates targeting…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
